Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Arvinas, Inc. (NASDAQ:ARVN) has earned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $57.50.

Several equities analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. Oppenheimer dropped their price target on shares of Arvinas from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 31st. HC Wainwright restated a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research report on Thursday, August 1st. Barclays dropped their target price on Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a report on Tuesday, July 30th.

Arvinas Stock Up 0.1 %

NASDAQ ARVN opened at $25.63 on Wednesday. The firm has a market cap of $1.75 billion, a P/E ratio of -4.32 and a beta of 1.97. Arvinas has a 52-week low of $13.57 and a 52-week high of $53.08. The business’s 50-day moving average price is $26.31 and its 200 day moving average price is $30.87.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, July 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.59. The company had revenue of $76.50 million during the quarter, compared to analyst estimates of $33.27 million. During the same period in the previous year, the firm posted ($1.25) EPS. The company’s revenue for the quarter was up 40.4% on a year-over-year basis. As a group, analysts anticipate that Arvinas will post -3.51 earnings per share for the current year.

Institutional Trading of Arvinas

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Arvinas by 29.9% in the first quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock valued at $260,046,000 after buying an additional 1,448,166 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Arvinas by 14.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,368,418 shares of the company’s stock worth $180,329,000 after buying an additional 536,295 shares in the last quarter. RTW Investments LP purchased a new position in Arvinas in the fourth quarter valued at about $173,427,000. Avidity Partners Management LP grew its position in shares of Arvinas by 14.2% during the fourth quarter. Avidity Partners Management LP now owns 2,985,117 shares of the company’s stock worth $122,867,000 after buying an additional 370,157 shares in the last quarter. Finally, Bellevue Group AG grew its holdings in Arvinas by 18.0% during the 4th quarter. Bellevue Group AG now owns 2,507,731 shares of the company’s stock worth $103,218,000 after acquiring an additional 382,531 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.